Why Clinical Supply Problems Rarely Start In Clinical Supply
By Ray Forslund, Ph.D., MBA, EVP, Head of Product development, Syner-G
Every stockout has a supply chain fingerprint on it by the time anyone notices. A site calls in, IRT throws an allocation error, a depot is short on a strength that was supposed to arrive weeks ago. So, the postmortem starts in supply chain, and it usually ends there too: a forecasting miss, a depot that under-ordered, a courier delay. I have sat through a lot of those postmortems, and in my experience the real decision that caused the problem was made three or four months earlier, in a room that had nothing to do with clinical operations. Sometimes that room was writing the protocol or building the enrollment forecast. Just as often, it was CMC, quality, or regulatory affairs, making a call that was entirely defensible on its own terms and never got translated into a supply consequence.
In 11 years of consulting, wearing a lot of different hats across CMC, clinical development, and quality, and having sat on both the sponsor side and the CDMO side of the same relationship, sometimes in the same year, one pattern stands out. Clinical supply is almost always the last function to feel the consequences of a decision and the first function to get blamed for it. The people who actually caused the shortage are usually two or three functions removed from the trial by the time it happens, and they rarely find out unless someone drags them into the room.
The Process Lock Date Is A Supply Commitment, Whether Anyone Treats It That Way Or Not
Process development teams talk about locking a manufacturing process as a scientific milestone. Clinical supply planners experience it as a scheduling constraint that determines whether a batch can run in time to support enrollment. Those two framings almost never get reconciled, and that gap is where a lot of trouble starts.
I have seen programs where a process change, driven by a legitimate yield or impurity concern, got pushed six weeks to the right without anyone in supply chain being told the batch calendar had moved. The CMC team solved a real problem and solved it well. But the campaign that was supposed to produce drug product for a Phase 2 readout got compressed into a window that no longer accommodated release testing, stability pull points, or comparator blinding activities on the other side of the process. By the time clinical supply saw the new date, there was no slack left to absorb it. The trial did not run out of drug because a depot mismanaged inventory. It ran out because a process change that made complete scientific sense was never translated into a supply commitment with a hard date attached to it.
The fix is not more forecasting rigor in the supply chain. The fix is treating the process lock date as a cross functional deliverable owned jointly by CMC and clinical supply, with the batch calendar recalculated and reissued the same week any process timeline moves, not at the next scheduled planning meeting.
Quality Release Queues Are A Hidden Inventory Position That Nobody Manages As Inventory
Every clinical supply plan assumes a release cycle time. Almost none of them treat that cycle time as a variable that quality can move without telling anyone. When a QA group takes on a backlog of deviations, a CAPA surge, or a new data integrity remediation effort, release timelines stretch quietly. Nobody announces it as a supply event because from inside quality it does not look like one. It looks like a batch sitting in a queue a little longer than usual.
I watched this play out on a program where a routine investigation into an out of specification result on an unrelated product pulled the QA reviewer who normally turned around clinical batch disposition in five business days. Disposition slipped to 12 days for two consecutive batches. Nobody escalated it because each individual delay looked minor. The cumulative effect was that finished goods arrived at the packaging site nine days later than the supply plan assumed, and that nine days was exactly the buffer that had been built in to cover shipping and site-level drug accountability reconciliation. The buffer existed. It just got consumed by something no one in clinical supply had visibility into.
Quality release cycle time should be forecasted and monitored the same way lead time and yield are, with a named owner accountable for flagging deviation from the assumed cycle time in real time, not at month end. If your supply plan has a release assumption baked into it, someone in quality needs to know that assumption exists and that it is being watched.
Regulatory CMC Timing Decides How Much Flexibility You Have Left When Something Breaks
The third place this shows up is regulatory CMC, specifically around the timing of amendments, comparability packages, and label or packaging changes. A regulatory strategy decision to bundle a manufacturing change into a planned annual report rather than file it as a stand-alone amendment can be entirely defensible from a regulatory efficiency standpoint. It can also mean that a new supplier, a new fill/finish site, or an updated specification is not available to use as a contingency source until months later than clinical operations assumed it would be.
I have seen this bite programs hardest around comparator sourcing and combination product labeling, where a packaging change that looks administrative to a regulatory affairs team is the exact change that clinical supply was counting on to resolve a randomization or blinding constraint. The regulatory timeline was optimized for filing. Nobody asked whether it was also optimized for the supply contingency plan that depended on it.
What To Do About It Next Quarter
The same logic extends past CMC, quality, and regulatory. Protocol amendments and enrollment forecasts create supply commitments, too, whether anyone in clinical operations frames them that way or not. But the fastest fix is the one closest to home. Stop running clinical supply risk reviews as a stand-alone meeting populated only by clinical operations and packaging vendors. Pull one CMC lead, one quality release owner, and one regulatory CMC lead into that review on a standing basis, and give each of them one job: flag any decision in their function from the prior four weeks that changes a date, a source, or a specification the supply plan depends on. Most clinical supply problems are not supply chain failures. They are communication failures with a supply chain consequence. Fixing the meeting invite list will do more for your stockout rate than any forecasting tool you are evaluating.
About The Author:
Ray Forslund has over 15 years of experience in the industry working for both pharmaceutical and CRO/CMO companies. As a member of the Syner-G executive leadership team, he leads the CMC Development and Project Management business unit. His team is responsible for providing scientific solutions for drug development programs, including identifying and managing CRO/CMO/CDMOs for Syner-G’s clients to support drug substance, drug product, and analytical development activities in biologics, small molecules, and peptides.